Metal Surface Compatible Gene Therapy


Site-specific delivery for in-stent restenonsis


Market Need


Cardiovascular diseases (CVD) are the leading cause of death in Europe, the United States and Japan and are expected to grow globally as the population ages. An effective treatment for coronary blockages resulting from CVD is stent implantation. The treatment though is short lived as restenosis, an immune response, develops around the stent. Polymer-coated gene-delivery stents have been shown to further prolong restenosis. Metal surface stents have a less pronounced inflammatory response than the polymer coated version but are not able to bind with gene vector delivery.


Technology Overview


The lab of Dr. Robert J. Levy developed a gene delivery that is able to bind on metallic stent surfaces. His team synthesized pollyallyamine bisphosphonate (PAA-BP) and demonstrated that it is able to bind on metal alloy surfaces (steel, nitinol, and cobalt-chromium). Further, his team showed the efficacy of the gene delivery system as treatment of in-stent restenosis using adenovirus expressing inducible nitric oxide synthase (Ad-iNOS) gene vector on cobalt-chromium stented arterial sections.



•       Limited nontarget tissue effects

•       Gene-delivery system compatible with various stent types

•       No inflammatory response due to polymer coating


•       Compatible with any metallic stent surfaces such as steel, nitinol, and cobalt-chromium


Stage of Development: In vivo proof of concept

Case ID:
Web Published:
Patent Information:
For Information, Contact:
Simone Temporal
Licensing Associate
The Children's Hospital of Philadelphia
Ivan Alferiev
Robert Levy
Ilia Fishbein
Gene Delivery